774-67-4

Usage

Uses

Used in Pharmaceutical Industry:
4-AMINO-N-ISOPROPYLBENZAMIDE is used as a chemical intermediate for the synthesis of various pharmaceuticals. Its unique structure allows it to be incorporated into the development of new drugs, potentially contributing to the creation of novel therapeutic agents.
Used in Agrochemical Industry:
In the agrochemical sector, 4-AMINO-N-ISOPROPYLBENZAMIDE is utilized as an intermediate in the production of agrochemicals. Its properties make it suitable for the synthesis of compounds that can be used in the development of pesticides, herbicides, and other agricultural chemicals to improve crop protection and yield.

InChI:InChI=1/C10H14N2O/c1-7(2)12-10(13)8-3-5-9(11)6-4-8/h3-7H,11H2,1-2H3,(H,12,13)

Upstream product

• 38681-76-4 N-isopropyl-4-nitrobenzamide 
• 150-13-0 4-amino-benzoic acid 
• 75-31-0 isopropylamine 
• 610-15-1 2-nitrobenzamide 

Downstream Products

• 947240-24-6 4-(2-bromoacetylamino)-N-isopropylbenzamide 
• 953039-71-9 2-(4-isopropylcarbamoyl-phenylamino)-6-((trimethylsilyl)ethynyl)-quinazolin-7-yl trifluoromethanesulfonate 
• 466694-70-2 methyl 3-(Z)-[1-{4-[isopropyl-carbamoyl]-phenylamino}-1-phenyl-methylidene]-2-indolinone-6-carboxylate 
• 1043-86-3 4-<2-Hydroxy-indanyl-(1)-amino>-N-isopropyl-benzamid 
• 70100-31-1 1--3,3-dimethyltriazene 

Relevant academic research and scientific papers

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Structure-activity relationships in the binding of chemically derivatized CD4 to gp120 from human immunodeficiency virus

The first step in HIV infection is the binding of the envelope glycoprotein gp120 to the host cell receptor CD4. An interfacial "Phe43 cavity" in gp120, adjacent to residue Phe43 of gp120-bound CD4, has been suggested as a potential target for therapeutic intervention. We designed a CD4 mutant (D1D2F43C) for site-specific coupling of compounds for screening against the cavity. Altogether, 81 cysteine-reactive compounds were designed, synthesized, and tested. Eight derivatives exceeded the affinity of native D1D2 for gp120. Structure-activity relationships (SAR) for derivatized CD4 binding to gp120 revealed significant plasticity of the Phe43 cavity and a narrow entrance. The primary contacts for compound recognition inside the cavity were found to be van der Waals interactions, whereas hydrophilic interactions were detected in the entrance. This first SAR on ligand binding to an interior cavity of gp120 may provide a starting point for structure-based assembly of small molecules targeting gp120-CD4 interaction.

Benzamide therapeutics for the treatment of inflammatory bowel disease

Benzamides are disclosed to be useful for treating and preventing inflammatory bowel disease.

Aminobenzamide compounds for the treatment of neurodegenerative disorders

A group of benzamide compounds are disclosed which are useful for treating neurodegenerative disorders. Methods for making these compounds are provided. These materials are formed into pharmaceutical compositions for oral or intravenous administration to patients suffering from conditions such as Parkinson's disease which can exhibit themselves as progressive loss of central nervous system function. The compounds can arrest or slow the progressive loss of function.